Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ASLAN Signs up JHL to Provide Process Development for Asthma Treatment

publication date: Nov 14, 2016
ASLAN Pharma of Singapore engaged JHL Biotech, a Taiwan/China CMO, to provide biologic process development services and clinical trial supplies of ASLAN004. ASLAN004 is a fully human monoclonal antibody that blocks the signaling of the IL-4 and IL-13 receptors. Work will start in 2016 in JHL's GMP-certified facility in Zhubei, Taiwan. ASLAN secured worldwide rights to ASLAN004 from CSL Behring in 2014, originally for asthma, though it is also developing the molecule to treat cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here